Arrakis Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
828 Winter St, Waltham, Massachusetts, 0...Website
www.arrakistx.comRevenue
$49 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.Explore more
Arrakis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arrakis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Arrakis Therapeutics is spiking on competitors!
Arrakis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Arrakis Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Arrakis Therapeutics
Check if Arrakis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Arrakis Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Arrakis Therapeutics launches new products
Earning: See what the market has to say on Arrakis Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Arrakis Therapeutics
Compare insights from companies similar to Arrakis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$11.2M
2010
JS
John SpringerSenior Director, Pharmaceutical Development Research & Development Project Management
Company Profile Activity
Activity Insights
Arrakis Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Arrakis Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Arrakis Therapeutics.
Arrakis Therapeutics financials insights
Gather financial insights about Arrakis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$38M
2019
Series B
$75M
Arrakis Therapeutics Tech Stack
A closer look at the technologies used by Arrakis Therapeutics
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Arrakis Therapeutics News & Media
Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)
Preclinical in vivo data demonstrate hyper-precise mechanism directly targets the disease-causing mRNA repeats leading to correction of splicing defects and reversal of myotoniaArrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will present preclinical data for its RNA-targeted small molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1), a form of muscular dystrophy. The data will be presented in an oral session at the Muscular Dystrophy Association (MDA) 2025 Clinical and Scientific CArrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy
WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced the first presentation of data for its RNA-targeted small molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1), a form of muscular dystrophy. These preclinical data demonstrate Arrakis’s leading-edge capability to rationally design a disease-modifying RNA-targeted small moleculArrakis Therapeutics to Present at Jefferies Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 3:30 p.m. ET in New York. About Arrakis Therapeutics Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of med
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Arrakis Therapeutics
Sign Up For FreeTo access detailed company insights
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA... Read More
